Champignon Brands Inc.

Champignon Brands Inc.

Champignon Brands Changes Name to Braxia Scientific to Reflect the Integration of Ketamine and Psychedelic Clinics and its Research and Development Priorities

TORONTO, May 3, 2021 - Champignon Brands Inc. (the "Company"), (CSE: SHRM) (FWB: 496) (OTCQB: SHRMF), is pleased to announce that it has changed its name from "Champignon Brands Inc." to "Braxia Scientific Corp." and its ticker symbol will change from "SHRM" to "BRAX" on the Canadian Securities Exchange (the "CSE").  The name change refle... Read More...

TSX Venture Exchange Stock Maintenance Bulletins

VANCOUVER, BC, March 4, 2021 - AZN Capital Corp. (the "Company" or "AZN") (TSXV: AZN) (OTC: AZNVF) is pleased to announce that it has received in excess of $900,000 from the exercise of warrants, options and brokers warrants since early February 2021.As previously announced, substantially all of the assets of the Company and its U.S. subs... Read More...

AZN Capital Provides Corporate Update

VANCOUVER, BC, March 4, 2021 - AZN Capital Corp. (the "Company" or "AZN") (TSXV: AZN) (OTC: AZNVF) is pleased to announce that it has received in excess of $900,000 from the exercise of warrants, options and brokers warrants since early February 2021.As previously announced, substantially all of the assets of the Company and its U.S. subs... Read More...

Golden Star Resources Reports Results for the Three and Twelve Months Ended December 31, 2020 Delivering on Increased 2020 Production Guidance at Wassa

- A $72M investmentLAVAL, QC, Nov. 12, 2020 /CNW Telbec/ - Urbania Development Corporation Inc., in partnership with the Fonds immobilier de solidarité FTQ, announces "Urbania haus": a unique residential complex situated in a strategic area of Laval, a stone's throw from the Montmorency metro station, Place Bell, university campuses, Coll... Read More...

Champignon Brands’ Canadian Rapid Treatment Center of Excellence Opens First Community-Based Centre in Ottawa to Provide Ketamine Treatment for Adults With Depression

Third CRTCE Clinic effectively addresses the unmet need of depression and suicide VANCOUVER, BC, Jan. 25, 2021 - Champignon Brands Inc. (the "Company"), (CSE: SHRM) (FWB: 496) (OTCQB: SHRMF), Chairman and CEO Roger McIntyre today announced the opening of a new Canadian Rapid Treatment Center of Excellence (CRTCE) clinic in Ottawa, Ontario... Read More...

Review of Bipolar Disorders Confirms Early Diagnosis and Treatment Can Improve Patient Quality of Life

VANCOUVER, BC, Jan. 8, 2021 - Champignon Brands Inc. (the "Company"), (CSE: SHRM) (FWB: 496) (OTCQB: SHRMF), announces the publication of an article led by Dr. Roger McIntyre, CEO of Champignon Brands Inc. The article – Bipolar Disorders – is published in one of the world's best-known and most reputable scientific journals in medicine - T... Read More...

Champignon Provides Update on Disclosure Review

VANCOUVER, British Columbia, Sept. 15, 2020 -- Champignon Brands Inc. (CSE: SHRM) (the “Company”) continues to work with the British Columbia Securities Commission (the “Commission”) to address an ongoing continuous disclosure review. Since the review was commenced, the Company has arranged for:Filing of business acquisition reports (coll... Read More...

Champignon to Begin Offering Esketamine Treatment for Adults With Major Depressive Disorder at the Canadian Rapid Treatment Centre of Excellence

VANCOUVER, British Columbia, Aug. 27, 2020 -- Champignon Brands Inc. (CSE: SHRM) (the “Company” or “Champignon”) is expanding its rapid-onset treatment service for major depressive disorder (“MDD”). Champignon will offer esketamine for the treatment of adults with MDD at its flagship clinic starting in September 2020. Ketamine was declare... Read More...

Champignon Announces Filing of Business Acquisition Reports and Appointment of Director

VANCOUVER, British Columbia, July 24, 2020 -- Champignon Brands Inc. (“Champignon” or the “Company”) (CSE: SHRM) (FWB: 496) (OTCQB: SHRMF) is pleased to announce it has filed business acquisition reports in connection with its previous acquisitions of Artisan Growers Ltd., Novo Formulations Ltd. and Tassili Life Sciences Corp. Copies of t... Read More...

Champignon Announces Regulatory Review

VANCOUVER, British Columbia, June 22, 2020 -- Champignon Brands Inc. (“Champignon” or the “Company”) (SHRM.CN) (496.F) (SHRMF) announces that it has been selected for a continuous disclosure review by the British Columbia Securities Commission (the “Commission”).  The review relates to the Company’s disclosure obligations since it became ... Read More...

Champignon’s Dr. Mcintyre / Canadian Rapid Treatment Centre of Excellence (CRTCE) Published in Two Peer Reviewed Study Journals

VANCOUVER, British Columbia, June 19, 2020 -- Champignon Brands Inc. (“Champignon” or the “Company”) (CSE: SHRM) (FWB: 496) (OTCQB: SHRMF), a human optimization sciences company with an emphasis on ketamine and psychedelic medicine, continues to highlight the scientific merit of its ketamine treatments for Major Depressive Disorder (MDD) ... Read More...

Champignon Provides Corporate Update; Announces Name Change, Rebranding and Planned Spin Out

VANCOUVER, British Columbia, June 12, 2020 -- Champignon Brands Inc. (“Champignon” or the “Company”) (CSE: SHRM) (FWB: 496) (OTCQB: SHRMF), a human optimization sciences company with an emphasis on ketamine and psychedelic medicine, since commencing trading on March 2, 2020 has expanded its initiatives and rapidly executed on such initiat... Read More...

Champignon Announces Closing of $15 Million Bought Deal Private Placement

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATESVANCOUVER, British Columbia, June 11, 2020 -- Champignon Brands Inc. (“Champignon” or the “Company”) (CSE: SHRM) (FWB: 496) (OTCQB: SHRMF), a human optimization sciences company with an emphasis on ketamine and psychedelic medicine, is please... Read More...

Champignon Identifies Synthetic Ketamine and Psilocybin/Psilicin Metabolite Targets; Selects Dalriada to Advance NCE IP Portfolio

VANCOUVER, British Columbia, June 08, 2020 -- Champignon Brands Inc. (“Champignon” or the “Company”) (SHRM.CN) (496.F) (SHRMF), a human optimization sciences company with an emphasis on ketamine and psychedelic medicine, is pleased to announce it has selected Toronto-based Dalriada Drug Discovery Inc. (“Dalriada”) to advance its new chemi... Read More...